Abstract

Nutraceuticals show promise in targeting oxidative stress and neuroinflammation-common underlying mechanisms in developmental disabilities such as autism, Down syndrome, fragile X syndrome, Rett syndrome, and cerebral palsy. Preclinical evidence indicates that compounds like curcumin, resveratrol, sulforaphane, N-acetylcysteine, coenzyme Q10, and omega-3 fatty acids reduce reactive oxygen species, boost antioxidant defenses, suppress microglial activation, and improve behavioral outcomes. Early human trials report benefits in irritability, social communication, and cognitive function, especially in autism and Down syndrome. Despite challenges such as poor bioavailability, lack of standardization, and limited pediatric safety data, nutraceuticals offer a safe adjunctive approach that warrants further research, including biomarker-guided and combination therapies.

Keywords: Nutraceuticals; Oxidative Stress; Neuroinflammation; Developmental Disabilities; Autism Spectrum Disorder; Curcumin; Resveratrol; Microglial Activation

Introduction

Developmental disabilities such as autism, Down syndrome, fragile X syndrome, and Rett syndrome originate in early brain development and persist throughout life. Oxidative stress and neuroinflammation are central pathophysiological mechanisms driving these conditions [1]. Oxidative stress arises from an imbalance between reactive oxygen species production and antioxidant defenses. Neuroinflammation involves chronic microglial activation and elevated pro‑inflammatory cytokines. The developing brain is especially vulnerable due to its high metabolic rate and immature antioxidant systems [2] Figure 1.

Nutraceuticals such as bioactive food compounds offer a promising dual approach to modulate both processes. The link between oxidative stress and neuroinflammation is bidirectional and self‑perpetuating. Reactive oxygen species activate NF‑κB, driving expression of IL‑1β, IL‑6, and TNF‑α. Inflammatory mediators, in turn, stimulate further reactive oxygen species production from microglial NADPH oxidase and mitochondria [3]. In autism, postmortem brains show elevated lipid peroxidation and microglial activation. Down syndrome features SOD1 overexpression due to chromosome 21 triplication, causing oxidative damage. Fragile X syndrome involves mitochondrial dysfunction, while Rett syndrome shows abnormal mitochondrial morphology and increased oxidative stress [4].

Key nutraceuticals with antioxidant properties include curcumin, resveratrol, sulforaphane, N‑acetylcysteine, coenzyme Q10, and alpha‑lipoic acid. They act through direct free radical scavenging, upregulation of endogenous antioxidant enzymes, and metal chelation. Curcumin reduces lipid peroxidation in rodent neurodevelopmental injury models [5]. Resveratrol activates the Nrf2‑ARE pathway, enhancing cellular defenses. Sulforaphane, an Nrf2 inducer, reduces oxidative stress in autism and fragile X models. N‑acetylcysteine replenishes glutathione, while coenzyme Q10 and alpha‑lipoic acid support mitochondrial antioxidant networks.

Many nutraceuticals also possess potent anti‑inflammatory properties by modulating microglial signaling. Curcumin inhibits NF‑κB activation and inflammatory gene transcription. Resveratrol suppresses IL‑1β and TNF‑α release via sirtuin‑1 activation [6]. Sulforaphane reduces microglial activation and iNOS expression, lowering nitric oxide. In perinatal hypoxia‑ischemia models, resveratrol and curcumin reduce microglial infiltration and preserve cognition. Omega‑3 fatty acids generate specialized pro‑resolving mediators that actively terminate inflammation [7].

Preclinical animal models strongly support nutraceutical efficacy in reducing oxidative stress and neuroinflammation. In BTBR autistic mice, curcumin improved social behavior and reduced oxidative markers. Resveratrol restored mitochondrial function and dendritic spines in fragile X mice. EGCG reduced oxidative DNA damage and improved memory in Down syndrome mice. N‑acetylcysteine attenuated motor deficits in a cerebral palsy model. Coenzyme Q10 extended survival and improved motor coordination in Rett syndrome mice [8]. These findings justify well‑designed human clinical trials. Human trials, though limited, have shown encouraging results, particularly in autism and Down syndrome.

N‑acetylcysteine reduced irritability in autistic children in a randomized controlled trial. Sulforaphane improved social interaction and verbal communication in young men with autism. A combination of EGCG, DHA, and antioxidants improved memory and brain connectivity in adults with Down syndrome. Pilot studies in fragile X syndrome and Rett syndrome have shown mixed but suggestive benefits. Heterogeneity in formulations and outcome measures complicates interpretation, yet early intervention targeting oxidative abnormalities appears promising [9].

Several significant challenges must be addressed before clinical integration. Bioavailability is a critical issue: curcumin and resveratrol are poorly absorbed and rapidly metabolized. Formulation strategies such as adjuvants or nanoparticles are needed to achieve therapeutic brain concentration. Long‑term safety data in pediatric populations are lacking for many nutraceuticals. Standardization of preparations varies widely, affecting purity and potency. Placebo effects in behavioral trials are substantial, requiring rigorous blinding and control conditions. Future research should focus on nutraceutical combinations that target multiple pathways simultaneously. Combining an Nrf2 activator, a radical scavenger, and a microglial modulator may produce synergistic effects [10]. Preclinical studies show that EGCG plus DHA and alpha‑lipoic acid improved memory more effectively than single agents. Another study found that curcumin, resveratrol, and N‑acetylcysteine normalized glutathione and microglial morphology. Biomarker‑driven approaches are needed to match combinations to individual oxidative/inflammatory profiles. Validated biomarkers in blood or urine are a high priority for the field [11].

In summary, accumulating evidence indicates nutraceuticals can modulate oxidative stress and neuroinflammation in developmental disabilities. Shared features across autism, Down syndrome, fragile X syndrome, and Rett syndrome provide a strong biological rationale. Early human trials show efficacy in reducing irritability and improving social communication with favorable safety profiles. However, challenges include poor bioavailability, lack of standardization, and limited pediatric safety data. Future research must improve delivery systems, identify biomarkers, and test rational combinations. With continued translational efforts, nutraceuticals can become valuable adjunctive components of comprehensive care..

References

1. Yang Z, Luo Y, Yang Z, Liu Z, Li M, et al. (2026) Mitochondrial dynamics dysfunction and neurodevelopmental disorders: From pathological mechanisms to clinical translation. Neural Regen Res 21(5): 1926-1946.
2. Trubalski M, Markiewicz-Gospodarek A, Żerebiec M, Poleszak J, Szczotka M, et al. (2025) Oxidative Stress-Mediated Neuroinflammation in the Pathophysiology of Schizophrenia. Int J Mol Sci 26(22): 11139.
3. Weinstock M (2025) Role of Oxidative Stress and Neuroinflammation in the Etiology of Alzheimer's Disease: Therapeutic Options. Antioxidants 14(7): 769.
4. Shareef AA, Kheder AH, Albarzinji N, Karim KJ, Smail SW, et al. (2025) Oxidative markers and SOD variant: predictors of autism severity and susceptibility. Future Sci OA 11(1): 2483628.
5. Gonzalez DE, Dickerson BL, Roberts BM, Kurtz JA, Waldman H, et al. (2026) International Society of Sports Nutrition position stand: effects of dietary antioxidants on exercise and sports performance. J Int Soc Sports Nutr 23(1): 2629828.
6. Davinelli S, Medoro A, Siracusano M, Savino R, Saso L, et al, (2025) Oxidative stress response and NRF2 signaling pathway in autism spectrum disorder. Redox Biol 83: 103661.
7. Fahey JW, Liu H, Batt H, Panjwani AA, Tsuji P (2025) Sulforaphane and Brain Health: From Pathways of Action to Effects on Specific Disorders. Nutrients 17(8): 1353.
8. Islam MR, Rauf A, Akter S, Akter H, Al-Imran MIK, et al. (2025) Neuroprotective Potential of Curcumin in Neurodegenerative Diseases: Clinical Insights Into Cellular and Molecular Signaling Pathways. J Biochem Mol Toxicol 39(8): e70369.
9. Ramos-Triguero A, Astals-Vizcaino M, Navarro-Tapia E, Vieiros M, Bastons-Compta A, et al. (2026) Cognitive and transcriptomic effects of Epigallocatechin gallate in fetal alcohol spectrum disorders. Sci Rep 16(1): 4461.
10. Fu Y, Ge Y, Yi S, Peng Q, Jiang H, et al. (2026) Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability. J Mater Sci Mater Med 37(1): 38.
11. Cavanah AM, Robinson LA, Aguilar MM, Molaison EF, Greene MW, ET AL. (2026) A Randomized Controlled Trial to Determine the Effects of Curcumin and Epigallocatechin-3-Gallate Supplementation on Serum Brain-Derived Neurotrophic Factor and Mood Disturbance in Adults. Nutrients 18(5): 855.